LISTED medical dermatology company Botanix Pharmaceuticals has announced the recruitment of first patients for its BTX 1503 Phase 2 acne clinical trial, following recent regulatory approvals and the earlier successful Phase 1b results.
Approximately 360 patients will be enrolled for a 12-week period in leading dermatology clinics across the US and Australia.
The Phase 2 acne clinical trial is fully funded and expected to take 12 months to complete.
Botanix executive director Matt Callahan said, "Based on the recent comments from FDA Commissioner around the approval of cannabidiol drug Epidiolex (PD yesterday), we are rapidly following the FDA's preferred development pathway and conducting well controlled clinical studies to demonstrate the safety and efficacy of BTX 1503 compared to vehicle (placebo)".
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Jun 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Jun 18
